ClinicalTrialsFinder

Hormone Receptor Positive HER-2 Negative Breast Cancer Clinical Trials in Philadelphia, Pennsylvania

1 recruitingPhiladelphia, Pennsylvania

Showing 1–1 of 1 trials

Recruiting
Phase 2

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Metastatic Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerRecurrent Breast Cancer
Puma Biotechnology, Inc.150 enrolled53 locationsNCT06369285